{"id":2225,"date":"2018-12-13T13:40:14","date_gmt":"2018-12-13T11:40:14","guid":{"rendered":"http:\/\/lupusgalicia.org\/?p=2225"},"modified":"2018-12-13T21:59:52","modified_gmt":"2018-12-13T19:59:52","slug":"estudio-dice-que-tratamiento-inmunosupresor-combinado-es-seguro-y-mas-eficaz-para-tratar-la-nefritis-lupus","status":"publish","type":"post","link":"https:\/\/lupusgalicia.org\/?p=2225","title":{"rendered":"Estudio dice que tratamiento inmunosupresor combinado es seguro y m\u00e1s eficaz para tratar la nefritis lupus"},"content":{"rendered":"<p><a href=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_750486493_zpsrpkras40-1400x480@2x.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-2226 aligncenter\" src=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_750486493_zpsrpkras40-1400x480@2x-300x180.jpg\" alt=\"\" width=\"390\" height=\"234\" srcset=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_750486493_zpsrpkras40-1400x480@2x-300x180.jpg 300w, https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_750486493_zpsrpkras40-1400x480@2x-768x461.jpg 768w, https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_750486493_zpsrpkras40-1400x480@2x-1024x614.jpg 1024w, https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_750486493_zpsrpkras40-1400x480@2x.jpg 1400w\" sizes=\"auto, (max-width: 390px) 100vw, 390px\" \/><\/a><\/p>\n<p><strong><span style=\"color: #800080;\">Un estudio aleatorizado encontr\u00f3 que\u00a0agregar un agente inmunosupresor oral e hidroxicloroquina a la ciclofosfamida intravenosa de rutina aumenta significativamente las tasas de respuesta entre los pacientes con\u00a0nefritis l\u00fapica\u00a0sin aumentar la tasa de eventos adversos graves.<\/span><\/strong><\/p>\n<p>El estudio,\u00a0 <span style=\"color: #800080;\">Tratamiento inmunosupresor combinado (CIST) en la nefritis l\u00fapica: un estudio multic\u00e9ntrico, aleatorizado y controlado<\/span>\u00a0, se public\u00f3 en\u00a0\u00a0Clinical Rheumatology\u00a0.<\/p>\n<p>La nefritis por lupus ocurre cuando hay inflamaci\u00f3n en los ri\u00f1ones como resultado del\u00a0lupus eritematoso sist\u00e9mico\u00a0.\u00a0Por lo general, se trata con terapias inmunosupresoras, que pueden disminuir la actividad inmunol\u00f3gica.<\/p>\n<p>La estrategia est\u00e1ndar para el\u00a0tratamiento\u00a0es ciclofosfamida o micofenolato mofetilo.\u00a0Sin embargo, solo una peque\u00f1a parte de los pacientes, hasta 1 de cada 4, experimenta una resoluci\u00f3n completa de la inflamaci\u00f3n despu\u00e9s de recibir estos tratamientos.<\/p>\n<p>Los investigadores en este estudio examinaron si la combinaci\u00f3n de ciclofosfamida con un inmunosupresor oral, como micofenolato mofetilo, azatioprina o leflunomida, ser\u00eda segura y eficaz para tratar la nefritis l\u00fapica.<\/p>\n<p>El estudio incluy\u00f3 a adultos con nefritis l\u00fapica de 17 centros de reumatolog\u00eda o nefrolog\u00eda en China.\u00a0Se les asign\u00f3 aleatoriamente ciclofosfamida (77 pacientes) o la combinaci\u00f3n (87 pacientes), administrada durante un per\u00edodo de 24 semanas.<\/p>\n<p>El grupo de combinaci\u00f3n tambi\u00e9n recibi\u00f3\u00a0\u00a0hidroxicloroquina\u00a0, una terapia antimal\u00e1rica com\u00fanmente utilizada para el tratamiento del lupus, y ambos grupos tambi\u00e9n recibieron\u00a0\u00a0glucocorticoides\u00a0, hormonas esteroides que tambi\u00e9n pueden ayudar a regular el sistema inmunol\u00f3gico.<\/p>\n<p>Los pacientes fueron analizados para determinar los marcadores de la funci\u00f3n renal, incluida la cantidad de prote\u00edna en orina y los niveles de alb\u00famina s\u00e9rica.\u00a0Se consider\u00f3 que ten\u00edan una respuesta completa si sus niveles eran casi normales o una respuesta parcial si experimentaban una disminuci\u00f3n del 50% en la prote\u00edna de la orina, ten\u00edan alb\u00famina s\u00e9rica de al menos 30 g \/ L y una funci\u00f3n renal estable.\u00a0Si no se alcanz\u00f3 ninguna respuesta, el tratamiento se consider\u00f3 un fracaso.<\/p>\n<p>En general, el 87.2% de los pacientes que recibieron la combinaci\u00f3n lograron una respuesta, en comparaci\u00f3n con el 68.8% de los que recibieron ciclofosfamida sola.\u00a0Las respuestas completas tambi\u00e9n fueron mayores con la combinaci\u00f3n (39,5% versus 20,8%), lo que demuestra que el tratamiento de combinaci\u00f3n fue m\u00e1s efectivo que el tratamiento con ciclofosfamida solo.<\/p>\n<p>Curiosamente, la leflunomida fue el inmunosupresor oral asociado con las mejores tasas de respuesta, con 89.8% de los pacientes respondiendo al tratamiento y 43.9% logrando una respuesta completa.<\/p>\n<p>Despu\u00e9s del ensayo de 24 semanas, los investigadores siguieron a 96 de los 128 pacientes que respondieron al tratamiento de inducci\u00f3n inicial.\u00a0Despu\u00e9s de una mediana de seguimiento de 13,5 meses, <strong><span style=\"color: #800080;\">menos pacientes que recibieron la combinaci\u00f3n experimentaron un brote renal<\/span><\/strong> (empeoramiento de los\u00a0s\u00edntomas\u00a0renales\u00a0) que los de ciclofosfamida (5,1% versus 10,8%), pero <strong><span style=\"color: #800080;\">los resultados no alcanzaron significaci\u00f3n estad\u00edstica.<\/span><\/strong><\/p>\n<p><span style=\"color: #800080;\"><strong>Las reacciones adversas tambi\u00e9n se evaluaron y no se encontraron diferencias significativas entre los dos grupos.<\/strong><\/span><\/p>\n<p><em><span style=\"color: #800080;\">\u201cLos pacientes bajo tratamiento combinado no experimentaron m\u00e1s eventos adversos.\u00a0Adem\u00e1s, la incidencia de eventos adversos graves que llevaron a la muerte, la hospitalizaci\u00f3n o el retiro del estudio no difiri\u00f3 entre los dos grupos \u00ab<\/span><\/em>, escribieron los investigadores.<\/p>\n<p>Tambi\u00e9n se\u00f1alan que los compuestos utilizados para la terapia de combinaci\u00f3n en este ensayo son agentes inmunosupresores tradicionales, no tratamientos biol\u00f3gicos que pueden ser m\u00e1s costosos.<\/p>\n<p><span style=\"color: #800080;\"><em>\u00abEl tratamiento inmunosupresor combinado es un r\u00e9gimen seguro y superior a la terapia de rutina [ciclofosfamida] para inducir la remisi\u00f3n en pacientes con LN [nefritis l\u00fapica]\u00bb,<\/em><\/span> concluyeron los investigadores.<\/p>\n<pre>Noticia de <a href=\"https:\/\/lupusnewstoday.com\/2018\/12\/12\/combined-immunosuppressive-treatment-safe-effective-lupus-nephritis-study\/\">LupusNewsToday<\/a> realizada por Marisa Wexler 12.12.18<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>Un estudio aleatorizado encontr\u00f3 que\u00a0agregar un agente inmunosupresor oral e hidroxicloroquina a la ciclofosfamida intravenosa de rutina aumenta significativamente las tasas de respuesta entre los pacientes con\u00a0nefritis l\u00fapica\u00a0sin aumentar la tasa de eventos adversos graves. El estudio,\u00a0 Tratamiento inmunosupresor combinado (CIST) en la nefritis l\u00fapica: un estudio multic\u00e9ntrico, aleatorizado y controlado\u00a0, se public\u00f3 en\u00a0\u00a0Clinical Rheumatology\u00a0. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2226,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[14,6,5],"tags":[44,19,42,16],"class_list":["post-2225","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-estudios","category-investigacion","category-lupus-internacional","tag-estudios","tag-informacion","tag-investigacion","tag-tratamientos"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\r\n<title>Estudio dice que tratamiento inmunosupresor combinado es seguro y m\u00e1s eficaz para tratar la nefritis lupus - Asociaci\u00f3n Galega de Lupus<\/title>\r\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\r\n<link rel=\"canonical\" href=\"https:\/\/lupusgalicia.org\/?p=2225\" \/>\r\n<meta property=\"og:locale\" content=\"es_ES\" \/>\r\n<meta property=\"og:type\" content=\"article\" \/>\r\n<meta property=\"og:title\" content=\"Estudio dice que tratamiento inmunosupresor combinado es seguro y m\u00e1s eficaz para tratar la nefritis lupus - Asociaci\u00f3n Galega de Lupus\" \/>\r\n<meta property=\"og:description\" content=\"Un estudio aleatorizado encontr\u00f3 que\u00a0agregar un agente inmunosupresor oral e hidroxicloroquina a la ciclofosfamida intravenosa de rutina aumenta significativamente las tasas de respuesta entre los pacientes con\u00a0nefritis l\u00fapica\u00a0sin aumentar la tasa de eventos adversos graves. El estudio,\u00a0 Tratamiento inmunosupresor combinado (CIST) en la nefritis l\u00fapica: un estudio multic\u00e9ntrico, aleatorizado y controlado\u00a0, se public\u00f3 en\u00a0\u00a0Clinical Rheumatology\u00a0. [&hellip;]\" \/>\r\n<meta property=\"og:url\" content=\"https:\/\/lupusgalicia.org\/?p=2225\" \/>\r\n<meta property=\"og:site_name\" content=\"Asociaci\u00f3n Galega de Lupus\" \/>\r\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LupusGalicia\/\" \/>\r\n<meta property=\"article:published_time\" content=\"2018-12-13T11:40:14+00:00\" \/>\r\n<meta property=\"article:modified_time\" content=\"2018-12-13T19:59:52+00:00\" \/>\r\n<meta property=\"og:image\" content=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_750486493_zpsrpkras40-1400x480@2x.jpg\" \/>\r\n\t<meta property=\"og:image:width\" content=\"1400\" \/>\r\n\t<meta property=\"og:image:height\" content=\"840\" \/>\r\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\r\n<meta name=\"author\" content=\"Agal\" \/>\r\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n<meta name=\"twitter:creator\" content=\"@LupusGalicia\" \/>\r\n<meta name=\"twitter:site\" content=\"@LupusGalicia\" \/>\r\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Agal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\r\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2225#article\",\"isPartOf\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2225\"},\"author\":{\"name\":\"Agal\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665\"},\"headline\":\"Estudio dice que tratamiento inmunosupresor combinado es seguro y m\u00e1s eficaz para tratar la nefritis lupus\",\"datePublished\":\"2018-12-13T11:40:14+00:00\",\"dateModified\":\"2018-12-13T19:59:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2225\"},\"wordCount\":618,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/lupusgalicia.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2225#primaryimage\"},\"thumbnailUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_750486493_zpsrpkras40-1400x480@2x.jpg\",\"keywords\":[\"Estudios\",\"Informaci\u00f3n\",\"Investigaci\u00f3n\",\"Tratamientos\"],\"articleSection\":[\"Estudios\",\"Investigaci\u00f3n\",\"Lupus Internacional\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/lupusgalicia.org\/?p=2225#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2225\",\"url\":\"https:\/\/lupusgalicia.org\/?p=2225\",\"name\":\"Estudio dice que tratamiento inmunosupresor combinado es seguro y m\u00e1s eficaz para tratar la nefritis lupus - Asociaci\u00f3n Galega de Lupus\",\"isPartOf\":{\"@id\":\"https:\/\/lupusgalicia.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2225#primaryimage\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2225#primaryimage\"},\"thumbnailUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_750486493_zpsrpkras40-1400x480@2x.jpg\",\"datePublished\":\"2018-12-13T11:40:14+00:00\",\"dateModified\":\"2018-12-13T19:59:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2225#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lupusgalicia.org\/?p=2225\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2225#primaryimage\",\"url\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_750486493_zpsrpkras40-1400x480@2x.jpg\",\"contentUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_750486493_zpsrpkras40-1400x480@2x.jpg\",\"width\":1400,\"height\":840},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2225#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/lupusgalicia.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Estudio dice que tratamiento inmunosupresor combinado es seguro y m\u00e1s eficaz para tratar la nefritis lupus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lupusgalicia.org\/#website\",\"url\":\"https:\/\/lupusgalicia.org\/\",\"name\":\"Asociaci\u00f3n Galega de Lupus\",\"description\":\"Trabajando para y por las personas con Lupus\",\"publisher\":{\"@id\":\"https:\/\/lupusgalicia.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lupusgalicia.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/lupusgalicia.org\/#organization\",\"name\":\"Asociaci\u00f3n Galega de Lupus\",\"url\":\"https:\/\/lupusgalicia.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png\",\"contentUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png\",\"width\":2560,\"height\":2522,\"caption\":\"Asociaci\u00f3n Galega de Lupus\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LupusGalicia\/\",\"https:\/\/x.com\/LupusGalicia\",\"https:\/\/www.instagram.com\/lupusgalicia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665\",\"name\":\"Agal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"caption\":\"Agal\"},\"description\":\"AGAL. Asociaci\u00f3n Galega de Lupus. Creada en 1997. Pretendemos dar informaci\u00f3n sobre el Lupus y que la enfermedad deje de ser una gran desconocida; ayudar a familiares y amigos; promover investigaci\u00f3n; divulgar y relacionar a nuestros asociados a trav\u00e9s de Jornadas, la revista Papilio, charlas, reuniones...\",\"sameAs\":[\"http:\/\/www.lupusgalicia.org\"],\"url\":\"https:\/\/lupusgalicia.org\/?author=1\"}]}<\/script>\r\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Estudio dice que tratamiento inmunosupresor combinado es seguro y m\u00e1s eficaz para tratar la nefritis lupus - Asociaci\u00f3n Galega de Lupus","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lupusgalicia.org\/?p=2225","og_locale":"es_ES","og_type":"article","og_title":"Estudio dice que tratamiento inmunosupresor combinado es seguro y m\u00e1s eficaz para tratar la nefritis lupus - Asociaci\u00f3n Galega de Lupus","og_description":"Un estudio aleatorizado encontr\u00f3 que\u00a0agregar un agente inmunosupresor oral e hidroxicloroquina a la ciclofosfamida intravenosa de rutina aumenta significativamente las tasas de respuesta entre los pacientes con\u00a0nefritis l\u00fapica\u00a0sin aumentar la tasa de eventos adversos graves. El estudio,\u00a0 Tratamiento inmunosupresor combinado (CIST) en la nefritis l\u00fapica: un estudio multic\u00e9ntrico, aleatorizado y controlado\u00a0, se public\u00f3 en\u00a0\u00a0Clinical Rheumatology\u00a0. [&hellip;]","og_url":"https:\/\/lupusgalicia.org\/?p=2225","og_site_name":"Asociaci\u00f3n Galega de Lupus","article_publisher":"https:\/\/www.facebook.com\/LupusGalicia\/","article_published_time":"2018-12-13T11:40:14+00:00","article_modified_time":"2018-12-13T19:59:52+00:00","og_image":[{"width":1400,"height":840,"url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_750486493_zpsrpkras40-1400x480@2x.jpg","type":"image\/jpeg"}],"author":"Agal","twitter_card":"summary_large_image","twitter_creator":"@LupusGalicia","twitter_site":"@LupusGalicia","twitter_misc":{"Escrito por":"Agal","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lupusgalicia.org\/?p=2225#article","isPartOf":{"@id":"https:\/\/lupusgalicia.org\/?p=2225"},"author":{"name":"Agal","@id":"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665"},"headline":"Estudio dice que tratamiento inmunosupresor combinado es seguro y m\u00e1s eficaz para tratar la nefritis lupus","datePublished":"2018-12-13T11:40:14+00:00","dateModified":"2018-12-13T19:59:52+00:00","mainEntityOfPage":{"@id":"https:\/\/lupusgalicia.org\/?p=2225"},"wordCount":618,"commentCount":0,"publisher":{"@id":"https:\/\/lupusgalicia.org\/#organization"},"image":{"@id":"https:\/\/lupusgalicia.org\/?p=2225#primaryimage"},"thumbnailUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_750486493_zpsrpkras40-1400x480@2x.jpg","keywords":["Estudios","Informaci\u00f3n","Investigaci\u00f3n","Tratamientos"],"articleSection":["Estudios","Investigaci\u00f3n","Lupus Internacional"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/lupusgalicia.org\/?p=2225#respond"]}]},{"@type":"WebPage","@id":"https:\/\/lupusgalicia.org\/?p=2225","url":"https:\/\/lupusgalicia.org\/?p=2225","name":"Estudio dice que tratamiento inmunosupresor combinado es seguro y m\u00e1s eficaz para tratar la nefritis lupus - Asociaci\u00f3n Galega de Lupus","isPartOf":{"@id":"https:\/\/lupusgalicia.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lupusgalicia.org\/?p=2225#primaryimage"},"image":{"@id":"https:\/\/lupusgalicia.org\/?p=2225#primaryimage"},"thumbnailUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_750486493_zpsrpkras40-1400x480@2x.jpg","datePublished":"2018-12-13T11:40:14+00:00","dateModified":"2018-12-13T19:59:52+00:00","breadcrumb":{"@id":"https:\/\/lupusgalicia.org\/?p=2225#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lupusgalicia.org\/?p=2225"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/lupusgalicia.org\/?p=2225#primaryimage","url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_750486493_zpsrpkras40-1400x480@2x.jpg","contentUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_750486493_zpsrpkras40-1400x480@2x.jpg","width":1400,"height":840},{"@type":"BreadcrumbList","@id":"https:\/\/lupusgalicia.org\/?p=2225#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/lupusgalicia.org\/"},{"@type":"ListItem","position":2,"name":"Estudio dice que tratamiento inmunosupresor combinado es seguro y m\u00e1s eficaz para tratar la nefritis lupus"}]},{"@type":"WebSite","@id":"https:\/\/lupusgalicia.org\/#website","url":"https:\/\/lupusgalicia.org\/","name":"Asociaci\u00f3n Galega de Lupus","description":"Trabajando para y por las personas con Lupus","publisher":{"@id":"https:\/\/lupusgalicia.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lupusgalicia.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/lupusgalicia.org\/#organization","name":"Asociaci\u00f3n Galega de Lupus","url":"https:\/\/lupusgalicia.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/","url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png","contentUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png","width":2560,"height":2522,"caption":"Asociaci\u00f3n Galega de Lupus"},"image":{"@id":"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LupusGalicia\/","https:\/\/x.com\/LupusGalicia","https:\/\/www.instagram.com\/lupusgalicia\/"]},{"@type":"Person","@id":"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665","name":"Agal","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","caption":"Agal"},"description":"AGAL. Asociaci\u00f3n Galega de Lupus. Creada en 1997. Pretendemos dar informaci\u00f3n sobre el Lupus y que la enfermedad deje de ser una gran desconocida; ayudar a familiares y amigos; promover investigaci\u00f3n; divulgar y relacionar a nuestros asociados a trav\u00e9s de Jornadas, la revista Papilio, charlas, reuniones...","sameAs":["http:\/\/www.lupusgalicia.org"],"url":"https:\/\/lupusgalicia.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/2225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2225"}],"version-history":[{"count":2,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/2225\/revisions"}],"predecessor-version":[{"id":2233,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/2225\/revisions\/2233"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/media\/2226"}],"wp:attachment":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}